Clinical Trials Logo

Idiopathic Pulmonary Fibrosis clinical trials

View clinical trials related to Idiopathic Pulmonary Fibrosis.

Filter by:

NCT ID: NCT02848625 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Yoga Effect on Quality of Life Study Among Patients With Idiopathic Pulmonary Fibrosis

YES-IPF
Start date: August 2016
Phase: N/A
Study type: Interventional

This study will evaluate whether regular yoga exercises designed specifically for patients with Idiopathic Pulmonary Fibrosis is associated with any change in quality of life. Half of the participants will be randomized to yoga, half to usual care. After the first group completes 12 weeks of yoga, the patients who were randomized to usual care will completed 12 weeks of yoga.

NCT ID: NCT02846324 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

Start date: June 2016
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.

NCT ID: NCT02827734 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)

Start date: October 2015
Phase: N/A
Study type: Observational

Current diagnostic tools used in interstitial lung disease (ILD) do not meet the challenges set by the complex pathophysiology of this heterogenous group. The investigators therefore aimed to evaluate novel or not widely used diagnostic approaches for the detection and therapeutic monitoring of patients with various ILDs.

NCT ID: NCT02821039 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Turkish Thoracic Society Usual Interstitial Pneumonia Registry Study

Turk-UIP
Start date: June 2016
Phase: N/A
Study type: Observational [Patient Registry]

The Turkish Thoracic Society Usual Interstitial Pneumonia Registry (Turk-UIP) is a collaborative project to coordinate a team of investigators from various regions of Turkey. The purpose of the Registry is to collect epidemiological data on patients with idiopathic pulmonary fibrosis and other causes of UIP, and to obtain information about the natural course of the disease and the treatment response.

NCT ID: NCT02818712 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up

Start date: August 2016
Phase: N/A
Study type: Observational

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a high mortality. Health-related quality of life (HRQL) is impaired in patients with IPF. Little is known about the properties of recently developed HRQL questionnaires and about the longitudinal changes in HRQL, including factors with an impact on HRQL. Comorbidities have an impact on patients with IPF, but reports differ in incidence and prevalence. The impact of comorbidities on HRQL and disease progression has only been studied sparsely. Also, the association between biomarkers and disease progression need to be examined further.

NCT ID: NCT02803580 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis

Start date: November 2015
Phase: N/A
Study type: Observational

The purpose of the present study is to evaluate the characteristics, management and clinical course of patients with IPF as treated under real-world in Italian Pulmonary Centres, in terms of symptoms, lung function and exercise tolerance during 12 months of observation.

NCT ID: NCT02802345 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Start date: June 2016
Phase: Phase 3
Study type: Interventional

Efficacy will be assessed by the change from baseline in St George's Respiratory Questionnaire (SGRQ) total score at week 12 and at week 24; by the change from baseline in dyspnea using the University of California San Diego Shortness of Breath Questionnaire (UCSC SOBQ) at week 12 and at week 24; whereas safety will be assessed by the percentage of patients with on-treatment Serious Adverse Events (SAE) from baseline to week 24.

NCT ID: NCT02788474 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Start date: June 2016
Phase: Phase 4
Study type: Interventional

Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.

NCT ID: NCT02772549 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay

Start date: March 2016
Phase: N/A
Study type: Observational [Patient Registry]

Patients with newly diagnosed IPF are investigated for the diagnostic delay before a diagnosis of IPF is made.

NCT ID: NCT02759120 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

CleanUP IPF for the Pulmonary Trials Cooperative

CleanUp-IPF
Start date: August 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of standard care, versus standard of care plus antimicrobial therapy (co-trimoxazole or doxycycline), on clinical outcomes in patients diagnosed with idiopathic pulmonary fibrosis (IPF).